摘要目的 探讨尿B2-微球蛋白(β2-microglobin,β2-MG)、尿微量白蛋白(Microalbuminuria,MA)及血清CysC与血清尿素(blood Urea)、肌酐(Cr)联合检测在化疗中对肾功能评价的临床意义.方法 将50例恶性肿瘤患者,分别在化疗前、化疗后1 d、3 d、7 d和15 d时测定血清CysC与UREA、Cr同时检测尿β2-MG、MA并进行分析比较.结果 β2-MG在化疗后1 d即开始升高,随后尿MA和血CysC均升高.化疗后尿β2-MG和尿MA及血清Cysc同化疗前相比有显著性差异.结论 尿β2-MG及MA和血清CysC具有较好的早期肾损伤诊断价值,且较血BUN、Cr更灵敏.

abstractsObjective To study the clinical significance of detecting the serum Cystatin C(CysC),Microalbuminuria(MA),β2-microglobin (β2-MG) and blood Urea (Urea),Creatinine (Cr) in cancer patients treated with chemotherapy.Methods Serum level of CysC,MA,β2-MG and Urea,Cr were detected in 50 patients with malignant tumor at baseline and 1,3,7,15 days after treated with chemotherapy respectively.Their levels pre-and post-chemotherapy were analysed.Results serum level of β2-MG increased significantly at 1 d postchemotherapy;Urea MA and serum CysC incerased simultaneously in the following days.The levels of CysC,MA,β2-MG were significant higher than that at baseline.Conclusion Detecting the levels of CysC,MA,β2-MG had a higher valuation in early diagnosing renal function damage and are more sensitive than blood Urea and Cr in the early diagnosis of renal function damage.